PER-013-10已完成未知
A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Patients With Type 2 Diabetes Mellitus
Astellas Pharma Global Development, Inc. (APGD),0 个研究点目标入组 0 人开始时间: 2010年6月10日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •The subject has a HbA1c value between 6.8 and 9.5% in Visit 1 AND has a HbA1c value between 7.0 and 9.5%, inclusive, in Visit 3 And does not meet any of the fasting criteria for fasting plasma glucose ( GPA) (see Section 3.4).
- •The subject is a virgin to antidiabetic medications; Or you are receiving a single low-dose antidiabetic agent for a double combination oral therapy (<50% of the maximum doses of each component), and you are willing and can safely discontinue the anti-diabetic therapy in the Selection (for 8 weeks at least before of the first dose of the study medication) and throughout the study (24 weeks in total).
- •The subject is on a stable diet and exercise program (at least for 6 weeks before Selection) and is willing to continue in this program during the study.
- •The subject has a body mass index (BMI) of 20-45 kg / m ^ 2 in Visit 1.
排除标准
- •The subject has some confirmed complication of DMT2, indicating a late state of the disease, which in the opinion of the Investigator must prevent the participation of! subject.
- •The subject has type l diabetes mellitus.
- •The subject needs insulin therapy or has received insulin within 3 months before Visit 1, except for acute use of <7 days.
- •The subject has a serum creatinine value greater than the normal upper limit on Visit 1 or 3.
- •The subject has an ALT and / or AST value greater than 3 times the normal upper limit or has a total bilirubin value greater than 2 times the normal upper limit on Visit 1 or 3.
- •The subject has a urine microalbumin / creatinine ratio> 300 mg / g on Visit 1 or 3.
- •The subject has a symptomatic urinary tract infection or a symptomatic genital infection at any time during the Selection or the Pre-Inclusion Period with Placebo, even immediately before random assignment at Visit 4.
- •The subject has persistent severe uncontrolled hypertension, indicated by a systolic blood pressure> 180 mmHg or a diastolic blood pressure> 110 mmHg taken in a sitting or supine position after 5 minutes of rest in 2 measurements at least (difference of 30 minutes between each) in Visits 1, 2 or 3.
- •The subject has significant cardiovascular disease, such as myocardial infarction or had a vascular intervention (for example, angioplasty or stent) within 3 months before Visit 1, or a history of heart failure (NYHA Class III-IV).
- •The subject is currently receiving an excluded medication (loop diuretics or systemic corticosteroids) or is not willing to suspend a restricted medication during the study.
- •The subject has a history of lactic acidosis.
- •The subject has a history of drug or alcohol abuse / dependence within 12 months prior to Visit 1, as defined in the Diagnostic and Statistics Manual-IV (DSM-IV).
- •The subject had a malignancy in the last 5 years, except for basal or squamous cell carcinoma of the skin or cervical carcinoma in situ successfully treated.
- •The subject has confirmed or suspected hypersensitivity to ASP1941 or metformin or its components.
研究者
相似试验
已完成
2 期
A study to evaluate the effect of ASP 1941 in adult patients with type 2 diabetes mellitusCTRI/2010/091/000343Astellas Pharma Inc378
招募中
2 期
A clinical trial to study the side effects of a drug, MBX-2982 and also to study how well it works and is tolerated when compared to a placebo and a comparator in patients with Type 2 Diabetes Mellitus.CTRI/2010/091/000162Metabolex Inc100
已完成
2 期
A Phase 2a Randomized, Double-Blind, Placebo and Active Comparator-Controlled, Parallel Group, Dose-Range Finding Study of MVT-602 in Healthy Premenopausal Women Undergoing Controlled Ovarian Stimulation (COS) Using a Minimal Stimulation Protocol.NL-OMON46304Myovant Sciences GmbH85
进行中（未招募）
1 期
A study to investigate the sex-hormone-stimulant study drug MVT-602 in healthy fertile women.EUCTR2018-001379-20-NLMyovant Sciences GmbH85
进行中（未招募）
不适用
A phase II, randomized, double-blind, placebo and active controlled, parallel group, multi-center, dose ranging study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks treatment in patients with resistant hypertension.MedDRA version: 9.1Level: LLTClassification code 10020772Term: Hypertensionresistant hypertensionEUCTR2008-007338-23-ISovartis Pharma Services AG250